Nathaniel Chartrand

Title: Nathaniel Chartrand: Innovator in CAR T-cell Therapy

Introduction

Nathaniel Chartrand is a prominent inventor based in Seattle, WA (US). He has made significant contributions to the field of cell therapy, particularly in the area of CAR T-cell therapy. His innovative work focuses on improving the safety and efficacy of therapeutic T cell compositions.

Latest Patents

Nathaniel Chartrand holds a patent for "Determining toxicity risk in CAR T-cell therapy." This patent outlines methods, compositions, and articles of manufacture for use in connection with cell therapy involving the administration of therapeutic T cell compositions. The T cell compositions express recombinant receptors, such as chimeric antigen receptors (CARs) or other transgenic receptors. The features of this invention, including the number of cells administered and the potency of those cells, provide advantages such as a lower risk of toxicity in subjects receiving the T cell compositions. He has 1 patent to his name.

Career Highlights

Chartrand is associated with Juno Therapeutics GmbH, where he continues to advance research in cell therapy. His work is pivotal in developing safer therapeutic options for patients undergoing CAR T-cell therapy.

Collaborations

Nathaniel has collaborated with notable colleagues, including Brian Christin and Michael Gerard Covington, contributing to the advancement of innovative therapies in the field.

Conclusion

Nathaniel Chartrand's contributions to CAR T-cell therapy exemplify the importance of innovation in medical science. His work not only enhances therapeutic options but also prioritizes patient safety.